Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100956 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02100956: Clinical Trial Phase 2 study, sponsored by Wake Forest University Health Sciences.
NCT02100956 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02100956, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effect of oxytocin given into the spinal fluid on pain and areas and intensity of hyperalgesia and allodynia in patients with chronic neuropathic pain.
Primary Outcome
Pain will be measured by visual analog scale, a 10 cm line with 0/"no pain" on the left end and 10/"pain as worse as can be" on the right end. The subject places a mark on the line and the score is determined by the distance in cm from the "no pain" end.
Interventions
- DRUG oxytocin 100 micrograms
- DRUG Normal Saline (preservative free)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-06-19 |
| Est. Completion | 2022-10-10 |
| Phase | Phase 2 |
Why NCT02100956 stopped before completion
NCT02100956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which oxytocin 100 micrograms is the first listed.
NCT02100956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02100956 about?
NCT02100956 is a clinical study titled "Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain". The purpose of the study is to determine the effect of oxytocin given into the spinal fluid on pain and areas and intensity of hyperalgesia and allodynia in patients with chronic neuropathic pain.
What is the current status of trial NCT02100956?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2014-06-19. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT02100956?
The interventions under investigation include: oxytocin 100 micrograms (DRUG), Normal Saline (preservative free) (DRUG).
Who is sponsoring clinical trial NCT02100956?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02100956's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI